This Week in Psychiatry — Jun 28, 2026

Welcome to This Week in Psychiatry. This week we are covering 9 notable papers spanning three broad themes: advanced precision targeting and neuromodulation, biological subtypes and biomarkers in major psychiatric disorders, and optimization of clinical care delivery. Let us dive in.

We begin this week with a focus on neuromodulation, where researchers are moving beyond standardized, one-size-fits-all approaches toward individualized, circuit-based therapies. In a randomized clinical trial published in JAMA Psychiatry, Taylor and colleagues evaluated whether guiding accelerated transcranial magnetic stimulation, or aTMS, using individualized functional connectivity neuroimaging improves outcomes for patients with treatment-resistant depression [8]. The trial randomized 40 adults with moderate to severe treatment-resistant depression to receive either connectivity-based or standard scalp-based aTMS targeting. For the connectivity-guided group, the target in the left dorsolateral prefrontal cortex was individualized based on pre-treatment resting-state functional connectivity scans, specifically looking for the region with the greatest correlation to a convergent depression circuit, which features negative connectivity to the subgenual cingulate cortex. The scalp-based group was targeted using the standard Beam F3 method. The investigators found that after one month, the median reduction in the Montgomery-Asberg Depression Rating Scale was 24 points in the connectivity-based group compared to 18 points in the scalp-based group. This represents a substantial clinical improvement, with an calculated effect size of 0.8 and a number needed to scan of just 5 individuals to achieve this superior outcome. The researchers also confirmed that these individualized targets were highly reproducible within the same patient but varied significantly between different patients, highlighting the limitations of standard scalp-based targeting. This trial provides some of the clearest evidence to date that incorporating baseline functional imaging to map individual brain circuitry can directly translate into superior clinical efficacy for transcranial magnetic stimulation.

In a parallel effort to modulate dysregulated brain networks, a study published in Molecular Psychiatry investigated the use of transcranial alternating current stimulation, or tACS, to target cortico-striatal-amygdalar networks in patients with opioid use disorder [1]. Soleimani and colleagues conducted a pre-registered, triple-blind, sham-controlled trial involving 60 male participants with opioid use disorder. The active group received 20 minutes of 6-Hertz theta-band tACS over the right frontoparietal network, using high-definition electrodes placed at the F4 and P4 positions, while the control group received a sham stimulation. Functional magnetic resonance imaging and craving assessments were performed immediately before and after the stimulation. Although the active stimulation did not produce a statistically significant difference in immediate subjective craving compared to the sham group, the neuroimaging data revealed significant network engagement. The active tACS group showed a significant decrease in post-stimulation opioid cue-related activity in key reward processing nodes, including the ventral striatum, the amygdala, and the ventral tegmental area. Furthermore, the active stimulation increased right frontoparietal network engagement and enhanced top-down inhibitory regulation from the frontoparietal network onto the right ventral striatum and the left medial amygdala. Interestingly, the strength of the electric field in the right frontal and parietal nodes predicted the degree of network engagement. These findings demonstrate that theta-band frontoparietal tACS can successfully engage and modulate the cortical-subcortical circuits that drive cue reactivity in addiction, offering a promising, non-invasive neuromodulatory avenue for supporting recovery, even if immediate behavioral changes in craving require longer-term or repeated treatment protocols.

Our second theme looks at the search for biological markers that can help us subtype psychiatric disorders and predict treatment responses, moving us closer to objective diagnostic criteria. A major individual participant data mega-analysis and meta-analysis published in JAMA Psychiatry investigated neurometabolite profiles associated with antipsychotic nonresponse in patients with psychosis [9]. King and colleagues pooled individual data from 18 studies, encompassing over 1,100 participants, and combined this with a meta-analysis of 23 studies. They compared neurometabolite levels in the medial frontal cortex, dorsolateral prefrontal cortex, thalamus, and basal ganglia between antipsychotic nonresponders, responders, and healthy controls. The mega-analysis revealed that, compared to treatment responders, nonresponders had significant elevations in medial frontal glutamate, glutamate plus glutamine, choline, and myo-inositol. These elevations were also present when comparing nonresponders to healthy controls. Notably, the elevation in medial frontal glutamate plus glutamine was observed prospectively in first-episode psychosis patients who went on to become nonresponders. Furthermore, the elevations in myo-inositol were most pronounced in individuals who met the formal criteria for treatment-resistant schizophrenia. These findings suggest that antipsychotic nonresponse is characterized by a distinct neurochemical profile marked by glutamatergic excess and potential neuroinflammation or membrane turnover, as indicated by elevated choline and myo-inositol. This neurobiological distinction supports the ongoing development and clinical testing of glutamate-targeting agents and anti-inflammatory interventions for patients who do not benefit from standard dopamine-receptor-blocking antipsychotics.

In a similar vein of subtyping major depressive disorder, a study published in Biological Psychiatry utilized machine learning and multi-center neuroimaging data to identify depression subtypes based on morphological-functional coupling [3]. Gao and colleagues analyzed discovery and validation cohorts totaling over 1,000 patients with major depressive disorder and more than 800 healthy controls. By examining the coupling between brain structure and function across different regions, they identified two highly replicable subtypes. Subtype One, characterized by overcoupling in association cortices, was linked to synaptic transmission pathways and clinically associated with more severe depressive symptoms, particularly psychomotor retardation, agitation, and hypochondriasis. Subtype Two, characterized by undercoupling in primary sensory and motor cortices, was linked to cell cycle-related pathways. While both subtypes shared common genetic enrichment for astrocyte and oligodendrocyte expression and dysregulation in serotonergic and GABAergic systems, they differed in treatment response. In a preliminary longitudinal cohort of 33 patients treated with escitalopram, patients belonging to the undercoupling subtype showed a more favorable clinical response, which was accompanied by a normalization of their morphological-functional coupling. This study provides a sophisticated framework that links macroscale brain network abnormalities with microscale cellular and genetic features, suggesting that structural-functional coupling could serve as a valuable biomarker for predicting antidepressant treatment outcomes and selecting appropriate therapies.

Our third theme addresses the practical aspects of clinical care, focusing on improving the delivery and accessibility of evidence-based treatments. For patients with bipolar disorder, lithium remains the gold-standard treatment, but the requirement for frequent venous blood draws to monitor therapeutic levels is a major barrier for both patients and clinicians. A study published in The British Journal of Psychiatry evaluated the acceptability and analytical performance of a novel point-of-care testing device, the Medimate Multireader, which measures lithium levels from a finger-prick sample [2]. Atkins and colleagues conducted surveys of patients and clinicians alongside an analytical validation against reference laboratory methods. The survey results revealed that a majority of both patients and clinicians preferred point-of-care testing over standard venous sampling. Patients reported that traditional venous monitoring was highly disruptive and inconvenient, and many indicated they would be far more willing to take lithium if home-based point-of-care monitoring were available. Clinicians identified the logistical demands of regular blood tests as the primary barrier to prescribing lithium. Crucially, the analytical validation showed excellent agreement between the point-of-care device and the reference laboratory method, with a correlation coefficient of 0.96 and a mean bias well within the predefined safe performance specification of plus or minus 0.2 millimoles per liter. These results suggest that point-of-care lithium monitoring is not only highly acceptable to patients but is also analytically robust enough to potentially transition lithium monitoring into the home or community setting, which could dramatically improve treatment adherence and safety.

Another critical area of clinical care delivery is the management of perinatal depression and anxiety, which affects one in five women globally. In a comprehensive systematic review and Bayesian network meta-analysis published in The British Journal of Psychiatry, Leng and colleagues evaluated 78 randomized controlled trials involving over 11,000 pregnant or postpartum women to compare the short- and long-term efficacy of various psychological treatments [6]. The analysis demonstrated that cognitive-behavioural therapy, or CBT, had the most consistent evidence of efficacy compared to treatment-as-usual, showing moderate confidence for reducing both post-intervention depression and anxiety, with benefits for depression sustained at long-term follow-up. Other modalities also showed short-term benefits over treatment-as-usual; interpersonal psychotherapy and mindfulness-based interventions were effective for short-term depression relief, while behavioural therapy and mindfulness-based interventions outperformed treatment-as-usual for short-term anxiety. However, among these secondary options, only behavioural therapy demonstrated a sustained long-term effect for anxiety. The researchers noted that differences in participant age, country income levels, and study risk of bias explained some of the heterogeneity in the results. Clinically, this network meta-analysis solidifies CBT as the first-line, gold-standard psychological intervention for perinatal distress, while highlighting that while mindfulness and interpersonal therapies are valuable short-term tools, they may require booster sessions or integration with other strategies to maintain long-term recovery.

Finally, we turn to two papers that advance our fundamental understanding of the cellular and genetic mechanisms underlying cognition and psychiatric risk. In a study published in Cell, Li and colleagues investigated the neural circuitry of sustained attention [4]. While cholinergic neurons in the basal forebrain have long been thought to drive attention, recent evidence has questioned this role. Using optogenetic manipulations in mice performing attention-demanding tasks, the authors discovered that parvalbumin-expressing inhibitory neurons in the basal forebrain play a crucial role in maintaining focus. The activity of these parvalbumin neurons predicted trial-by-trial fluctuations in reaction time and accuracy. Optogenetic activation of these cells enhanced attentional performance, while inhibition impaired it. Mechanistically, these basal forebrain parvalbumin neurons project to and target cortical parvalbumin-expressing interneurons, leading to a disinhibitory cortical amplification that enhances signal detection sensitivity based on motivational salience. This discovery identifies a specific, non-cholinergic projection that regulates cortical gain and could represent a novel therapeutic target for attention-deficit disorders. At the genetic level, a study published in Science explored how disease-associated genetic variants might remain hidden unless neurons are actively stimulated [5]. Liang and colleagues performed single-nucleus multiomics on induced pluripotent stem cell-derived neurons from 100 donors under resting and activated conditions. They identified numerous genetic variants associated with activity-dependent gene expression and chromatin accessibility, with the latter explaining a significantly larger proportion of neuropsychiatric disorder heritability than resting-state genetics. By integrating this multiomics data with genome-wide association studies, they uncovered novel risk variants and genes whose effects were only detectable upon neuronal stimulation, such as those involved in activity-dependent cholesterol metabolism. This work underscores the critical importance of context-specific and activity-dependent genetic screening to fully map the functional architecture of psychiatric risk.

If you only have time for one paper this week, make it the randomized clinical trial of connectivity-guided accelerated transcranial magnetic stimulation by Taylor and colleagues, published in JAMA Psychiatry [8]. This study provides a critical, rigorous proof of concept showing that using functional connectivity to individualize brain stimulation targets significantly outperforms standard scalp-based targeting, offering a clear path toward personalized, highly effective neuromodulation in daily clinical practice.

Here are the key takeaways from this week in Psychiatry. First, individualized, connectivity-based targeting for accelerated transcranial magnetic stimulation significantly improves antidepressant efficacy compared to standard scalp-based targeting, yielding a larger reduction in depression scores with a low number needed to scan. Second, point-of-care lithium monitoring using finger-prick testing is highly accurate, correlates strongly with laboratory reference methods, and is widely preferred by patients and clinicians, offering a viable path to reduce the logistical barriers of lithium therapy. Third, antipsychotic nonresponse in psychosis is characterized by distinct elevations in medial frontal glutamate, choline, and myo-inositol, reinforcing the potential of glutamatergic and anti-inflammatory pathways as alternative therapeutic targets. Fourth, cognitive-behavioural therapy remains the most consistently supported psychological treatment for both perinatal depression and anxiety, with demonstrated long-term benefits, especially for depression. And finally, basic science highlights that parvalbumin-expressing basal forebrain projections are critical for sustained attention, while genomic risk for psychiatric disorders is heavily influenced by activity-dependent genetic variants that are only detectable during active neuronal stimulation.

That's your roundup for This Week in Psychiatry. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And for audio briefings on your own clinical questions and papers, visit audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.